Jean Christophe Plantier

Summary

Affiliation: Rouen University Hospital
Country: France

Publications

  1. ncbi Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic
    Francis Barin
    Universite Francois Rabelais, Centre National de Référence du VIH and Inserm Espri EA 3856, Tours, France
    J Med Virol 78:S13-8. 2006
  2. ncbi Plasma RNA quantification and HIV-1 divergent strains
    Jean Christophe Plantier
    Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 33:1-7. 2003
  3. ncbi Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups
    Edouard Tuaillon
    Laboratoire de Virologie, Centre Hospitalier Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 37:1543-9. 2004
  4. ncbi Differences in proviral DNA load between HIV-1- and HIV-2-infected patients
    Marie Gueudin
    Laboratoire de Virologie, CHU Charles Nicolle Rouen, France
    AIDS 22:211-5. 2008
  5. ncbi Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Marie Gueudin
    Laboratoire de Virologie, Hopital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Virol Methods 113:43-9. 2003
  6. doi National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France
    J Antimicrob Chemother 68:2626-31. 2013
  7. pmc Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France
    Antimicrob Agents Chemother 54:4016-9. 2010
  8. ncbi French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:545-52. 2005
  9. doi Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, CHU de Rouen, Rouen, France
    J Acquir Immune Defic Syndr 56:139-45. 2011
  10. doi A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013

Detail Information

Publications36

  1. ncbi Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic
    Francis Barin
    Universite Francois Rabelais, Centre National de Référence du VIH and Inserm Espri EA 3856, Tours, France
    J Med Virol 78:S13-8. 2006
    ....
  2. ncbi Plasma RNA quantification and HIV-1 divergent strains
    Jean Christophe Plantier
    Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 33:1-7. 2003
    ..In conclusion, the authors showed that the LCx kit allowed quantification of the large group M diversity and group O variants...
  3. ncbi Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups
    Edouard Tuaillon
    Laboratoire de Virologie, Centre Hospitalier Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 37:1543-9. 2004
    ..To compare RT-based phenotype with recombinant virus assay (RVA) phenotype- and genotype-based analysis. To assess group O and HIV-2 susceptibility to NNRTIs in correlation with genotype polymorphisms...
  4. ncbi Differences in proviral DNA load between HIV-1- and HIV-2-infected patients
    Marie Gueudin
    Laboratoire de Virologie, CHU Charles Nicolle Rouen, France
    AIDS 22:211-5. 2008
    ....
  5. ncbi Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Marie Gueudin
    Laboratoire de Virologie, Hopital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Virol Methods 113:43-9. 2003
    ..Despite the high initial cost of acquiring the required cycling device, the per-sample cost of this real-time quantitative PCR assay for HIV-1 group O is low, making it suitable for use in endemic zones...
  6. doi National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France
    J Antimicrob Chemother 68:2626-31. 2013
    ..As recommended by the French ANRS programme for the surveillance of HIV-1 resistance, we estimated the prevalence of transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients...
  7. pmc Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France
    Antimicrob Agents Chemother 54:4016-9. 2010
    ..Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients...
  8. ncbi French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:545-52. 2005
    ..To survey the frequency of genotypic antiretroviral resistance and the spread of non-B subtypes in patients with primary HIV-1 infection (2001-2002) and in treatment-naive chronically HIV-1-infected patients (2001)...
  9. doi Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, CHU de Rouen, Rouen, France
    J Acquir Immune Defic Syndr 56:139-45. 2011
    ....
  10. doi A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013
    ..RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR...
  11. pmc Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG
    Jean Christophe Plantier
    Laboratoire de Virologie, Equipe d Accueil 2639, Universite Francois Rabelais, Tours, France
    J Clin Microbiol 40:1010-22. 2002
    ..This method can be adapted to the local situation by including only probes that correspond to the prevalent strains...
  12. pmc A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection
    Marie Gueudin
    Laboratoire associé au Centre National de Référence du VIH, Hopital Charles Nicolle, CHU de Rouen, Rouen, France
    J Clin Microbiol 50:831-6. 2012
    ..Its detection limit is equivalent to that of commercial kits. This assay is cheap and suitable for use in areas in which strains of HIV-1 groups M and O cocirculate...
  13. ncbi A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes
    Josephine Braun
    Laboratoire de Virologie, Biostatistique, Centre Hospitalier Charles Nicolle, 1 rue de Germont, 76031 Rouen Cedex, France
    AIDS 17:331-6. 2003
    ..In developing countries, viral load assay is either unaffordable or hindered by on-site maintenance and/or technical problems...
  14. pmc Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots
    Séverine Mercier-Delarue
    Laboratoire de Virologie, AP HP Hôpital Saint Louis, INSERM U941 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
    J Clin Microbiol 52:52-6. 2014
    ..This higher specificity of NASBA technology could avoid overestimation of poor compliance or the emergence of resistance when monitoring antiretroviral efficacy with the DBS method. ..
  15. pmc New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load
    Véronique Avettand-Fenoel
    Laboratoire de Virologie, AP HP, Hopital Necker Enfants Malades, Paris, France EA7327, Universite Paris Descartes, Sorbonne Paris Cité, Faculte de Medecine, Paris, France
    J Clin Microbiol 52:3017-22. 2014
    ..This new assay is highly sensitive and accurately quantifies the most prevalent HIV-2 groups. This test will be useful for monitoring low viral loads in HIV-2-infected patients. ..
  16. doi Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France
    Marie Leoz
    aLaboratoire associé au CNR du VIH, Hopital Ch Nicolle, CHU de Rouen bGRAM EA 2656, Faculte de Medecine Pharmacie, Universite de Rouen, Rouen, France cComputational and Evolutionary Biology research group, Faculty of Life Science, University of Manchester, Manchester, UK dAssistance Publique Hopitaux de Paris, Groupe Hospitalier Bichat Claude Bernard, Service de Virologie eAssistance Publique Hopitaux de Paris, Groupe Hospitalier Saint Louis, Service de Virologie, fAssistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Service de Virologie, Paris, France
    AIDS 27:2309-12. 2013
    ..We describe this new Circulating Recombinant Form, CRF56_cpx, estimate the time to its most recent common ancestor, investigate its origins and show that it probably shares common ancestors with strains from the East Mediterranean. ..
  17. ncbi HIV-1 resistance genotyping on dried serum spots
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, Rouen, France
    AIDS 19:391-7. 2005
    ....
  18. ncbi Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 65:2620-7. 2010
    ..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
  19. ncbi Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes
    Marie Gueudin
    Laboratoire de Virologie, Equipe d accueil 2656, Centre Hospitalier Universitaire Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Acquir Immune Defic Syndr 44:500-5. 2007
    ..We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16])...
  20. ncbi HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  21. doi Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays
    Jean Marie Sire
    Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
    J Acquir Immune Defic Syndr 56:239-43. 2011
    ..A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version...
  22. doi HIV-1 and HIV-2 produce different amounts of 2-long terminal repeat circular DNA in vitro
    Marie Gueudin
    Laboratoire de virologie UPRES EA 2656 Laboratoire associé du centre de référence pour VIH, CHU Charles Nicolle 76031 ROUEN Cedex, France
    AIDS 22:2543-5. 2008
    ..This accumulation of HIV-2 2-LTR DNA points to less efficient host cell integration relative to HIV-1...
  23. doi Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study
    Cecile Henquell
    CHU de Clermont Ferrand, Centre de Biologie, Laboratoire de Virologie, F 63003 Clermont Ferrand, France
    Infect Genet Evol 11:496-503. 2011
    ..Phylodynamic analyses give a plausible reconstruction of the evolutionary history of HCV genotype 5a in France, suggesting the concomitant roles of transfusion, iatrogenic route and intra-familial transmission in viral diffusion...
  24. ncbi HIV-1 group M superinfection in an HIV-1 group O-infected patient
    Jean Christophe Plantier
    AIDS 18:2444-6. 2004
  25. pmc Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 42:5866-70. 2004
    ..3% of group A or B samples; isolate H was not detected. This method allowed rapid and specific discrimination between HIV-2 groups A and B and could be a useful tool for molecular epidemiological studies...
  26. ncbi Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O
    Marie Gueudin
    J Acquir Immune Defic Syndr 36:639-41. 2004
  27. ncbi Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France
    Caroline Semaille
    Institut de Veille Sanitaire, Saint Maurice, 94 415, France
    J Infect Dis 196:377-83. 2007
    ..New tools to better monitor dynamics of human immunodeficiency virus (HIV) transmission are needed...
  28. ncbi Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa
    Jean Pierre Lombart
    Hôpital Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso
    AIDS 19:1273-7. 2005
    ..In resource-limited settings, the requirement for inexpensive, easy-to-perform viral load monitoring has increased with greater antiretroviral drug availability...
  29. ncbi Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test
    Francois Rouet
    Laboratoire de Virologie, Centre Muraz, BP 390 Bobo Dioulasso 01, Burkina Faso
    J Acquir Immune Defic Syndr 45:380-8. 2007
    ..Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays...
  30. ncbi Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  31. ncbi Molecular epidemiology of hepatitis B virus in Dakar, Sénégal
    Muriel Vray
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    J Med Virol 78:329-34. 2006
    ..These results underline the importance of molecular characterization of HBV infection as specific treatments become available in this region...
  32. doi Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy
    Raoudha Dachraoui
    J Acquir Immune Defic Syndr 47:522-5. 2008
  33. doi Integrase polymorphism and HIV-1 group O diversity
    Marie Leoz
    AIDS 22:1239-43. 2008
  34. doi Unequal detection of HIV type 1 group O infection by simple rapid tests
    Agnes Gautheret-Dejean
    Clin Infect Dis 46:1936-7. 2008
  35. pmc Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissible par le Sang, Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015 Paris, France
    J Clin Microbiol 43:733-9. 2005
    ....
  36. ncbi Generic screening test for HIV infection
    Jean Christophe Plantier
    AIDS 20:1345-7. 2006